勃林格殷格翰启动中国外部创新合作中心 - 2020年07月03日

German pharmaceutical company Boehringer Ingelheim announced on Thursday the launch of the External Innovation Hub China in Shanghai as part of its efforts to better leverage partnerships in research and development.
In the next five years, the company will invest 451 million euros (US$507.9 million) in China to fuel clinical research, production site expansions and other research partnerships.
“Boehringer Ingelheim will continue to increase investment in China, including setting up the External Innovation Hub, which will become one of Boehringer Ingelheim’s strategic pillars,” said Felix Gutsche, president and CEO of Boehringer Ingelheim China.